Trials / Completed
CompletedNCT04276428
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus
A Multiple-Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 in Japanese Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Japanese participants with type 2 diabetes. Side effects and tolerability will be documented. Blood samples will be taken to compare how the body handles the drug and how it affects blood sugar levels. The study will last almost five months for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3209590 | Administered SC. |
| DRUG | Insulin Degludec | Administered SC. |
Timeline
- Start date
- 2020-02-28
- Primary completion
- 2020-11-28
- Completion
- 2020-11-28
- First posted
- 2020-02-19
- Last updated
- 2020-12-03
Locations
3 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04276428. Inclusion in this directory is not an endorsement.